Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytek Biosciences Inc (CTKB)

Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 789,612
  • Shares Outstanding, K 128,811
  • Annual Sales, $ 193,020 K
  • Annual Income, $ -12,150 K
  • EBIT $ -24 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.32
  • Price/Sales 4.02
  • Price/Cash Flow 235.89
  • Price/Book 2.03

Options Overview Details

View History
  • Implied Volatility 148.81% ( -26.15%)
  • Historical Volatility 101.13%
  • IV Percentile 82%
  • IV Rank 54.31%
  • IV High 268.34% on 04/22/24
  • IV Low 6.73% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 40
  • Open Int (30-Day) 172

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.06
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate 0.04
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.66 +31.55%
on 10/25/24
7.63 -19.66%
on 11/07/24
+0.96 (+18.57%)
since 10/18/24
3-Month
4.66 +31.55%
on 10/25/24
7.63 -19.66%
on 11/07/24
+0.60 (+10.85%)
since 08/19/24
52-Week
4.66 +31.55%
on 10/25/24
9.87 -37.89%
on 12/26/23
+0.15 (+2.51%)
since 11/17/23

Most Recent Stories

More News
Cytek Biosciences Named "Overall BioTech Company of the Year" in 2024 BioTech Breakthrough Awards

Cytek Biosciences received the "Overall BioTech Company of the Year" award for advancements in cell analysis technology.Quiver AI SummaryCytek Biosciences, Inc. has been awarded "Overall BioTech Company...

CTKB : 6.13 (+1.66%)
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

CTKB : 6.13 (+1.66%)
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

CTKB : 6.13 (+1.66%)
Cytek Biosciences Reports Third Quarter 2024 Financial Results

CTKB : 6.13 (+1.66%)
Cytek Biosciences to Participate in Upcoming Investor Conferences

CTKB : 6.13 (+1.66%)
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024

CTKB : 6.13 (+1.66%)
Why Shares of Cytek Biosciences Dropped This Week

Cytek grew revenue and losses in the first quarter.

CTKB : 6.13 (+1.66%)
Cytek Biosciences Set to Join S&P SmallCap 600

/PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening...

SPGI : 502.31 (-0.14%)
CTKB : 6.13 (+1.66%)
CSII : 20.00 (+0.15%)
ABT : 117.13 (-0.20%)
Cytek Biosciences Reports Second Quarter 2022 Financial Results

Second quarter revenue grew 32% compared to prior year...

CTKB : 6.13 (+1.66%)
Cytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company...

CTKB : 6.13 (+1.66%)

Business Summary

Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.

See More

Key Turning Points

3rd Resistance Point 6.75
2nd Resistance Point 6.44
1st Resistance Point 6.29
Last Price 6.13
1st Support Level 5.83
2nd Support Level 5.52
3rd Support Level 5.37

See More

52-Week High 9.87
Fibonacci 61.8% 7.88
Fibonacci 50% 7.26
Fibonacci 38.2% 6.65
Last Price 6.13
52-Week Low 4.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar